Patent ID: 8796295

Claim:
A compound, or a pharmaceutically acceptable salt thereof, having a structure represented by a formula: wherein A is CR 2 or N; wherein L is O or NR 7 , wherein R 1 is a five-membered or six-membered monocyclic heteroaromatic ring substituted with 0-3 of R 9 ; wherein R 2 is hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, amino, hydroxyl, alkylamino, dialkylamino, NO 2 , CN, SO 2 R 8 , or COR 8 ; wherein R 3 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, and CN; wherein R 4 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C1-C6 haloalkoxy, hydroxyl, amino, alkylamino, dialkylamino, CN, SO 2 R 8 , and COR 8 , with the proviso that when A is N, then R 4 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, CN, SO 2 R 8 , and COR 8 ; wherein R 5 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, CN, SO 2 R 8 , and COR 8 ; wherein R 6 is selected from hydrogen, halogen, CN, C1-C6 alkyl, C3-C4 cycloalkyl, C3-C4 halocycloalkyl and C1-C6 haloalkyl; wherein each of R 6a , R 6b , and R 6c is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 haloalkoxy; wherein R 7 is hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl; wherein R 8 is C1-C6 alkyl, C1-C6 cycloalkyl, amino, alkylamino, or dialkylamino; and wherein each R 9 , when present, is independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C4 cycloalkyl, C3-C4 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxyl, amino, alkylamino, dialkylamino, NO 2 , CN, SO 2 R 8 , or COR 8 ; wherein the compound exhibits partial or total inhibition of mGluR5 response to glutamate as a decrease in response to non-maximal concentrations of glutamate in human embryonic kidney cells transfected with rat mGluR5 in the presence of the compound, compared to the response to glutamate in the absence of the compound.